Therapeutic strategies for EGFR-mutated non-small cell lung cancer patients with osimertinib resistance

Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are the preferential options for advanced non-small cell lung cancer (NSCLC) patients harboring EGFR mutations. Osimertinib is a potent irreversible third-generation EGFR-TKI targeting EGFR mutations but has little effect on wil...

Full description

Saved in:
Bibliographic Details
Published inJournal of hematology and oncology Vol. 15; no. 1; pp. 173 - 32
Main Authors Fu, Kai, Xie, Fachao, Wang, Fang, Fu, Liwu
Format Journal Article
LanguageEnglish
Published England BioMed Central Ltd 08.12.2022
BioMed Central
BMC
Subjects
Binding sites
Cancer
Cancer therapies
Carcinoma, Non-Small-Cell Lung - drug therapy
Carcinoma, Non-Small-Cell Lung - genetics
Care and treatment
Chemotherapy
Clinical trials
Drug Resistance, Neoplasm
EGFR-TKIs
Epidermal growth factor
Epidermal growth factor receptors
ErbB Receptors - genetics
Etiology
Genetic aspects
Health aspects
Hematology
Humans
Kinases
Ligands
Lung cancer
Lung cancer, Non-small cell
Lung cancer, Small cell
Lung Neoplasms - drug therapy
Lung Neoplasms - genetics
Metastases
Mutation
Non-small cell lung carcinoma
NSCLC
Oncology
Osimertinib
Protein-tyrosine kinase receptors
Resistance mechanisms
Review
Small cell lung carcinoma
Targeted cancer therapy
Targeted therapy
Therapeutic strategy
Tyrosine
Chemotherapy
NSCLC
Targeted therapy
Immunotherapy
EGFR-TKIs
Precise medicine
Osimertinib
Therapeutic strategy
Resistance mechanisms
Online AccessGet full text

Cover

Abstract Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are the preferential options for advanced non-small cell lung cancer (NSCLC) patients harboring EGFR mutations. Osimertinib is a potent irreversible third-generation EGFR-TKI targeting EGFR mutations but has little effect on wild-type EGFR. In view of its remarkable efficacy and manageable safety, osimertinib was recommended as the standard first-line treatment for advanced or metastatic NSCLC patients with EGFR mutations. However, as the other EGFR-TKIs, osimertinib will inevitably develop acquired resistance, which limits its efficacy on the treatment of EGFR-mutated NSCLC patients. The etiology of triggering osimertinib resistance is complex including EGFR-dependent and EGFR-independent pathways, and different therapeutic strategies for the NSCLC patients with osimertinib resistance have been developed. Herein, we comprehensively summarized the resistance mechanisms of osimertinib and discuss in detail the potential therapeutic strategies for EGFR-mutated NSCLC patients suffering osimertinib resistance for the sake of the improvement of survival and further achievement of precise medicine.
AbstractList Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are the preferential options for advanced non-small cell lung cancer (NSCLC) patients harboring EGFR mutations. Osimertinib is a potent irreversible third-generation EGFR-TKI targeting EGFR mutations but has little effect on wild-type EGFR. In view of its remarkable efficacy and manageable safety, osimertinib was recommended as the standard first-line treatment for advanced or metastatic NSCLC patients with EGFR mutations. However, as the other EGFR-TKIs, osimertinib will inevitably develop acquired resistance, which limits its efficacy on the treatment of EGFR-mutated NSCLC patients. The etiology of triggering osimertinib resistance is complex including EGFR-dependent and EGFR-independent pathways, and different therapeutic strategies for the NSCLC patients with osimertinib resistance have been developed. Herein, we comprehensively summarized the resistance mechanisms of osimertinib and discuss in detail the potential therapeutic strategies for EGFR-mutated NSCLC patients suffering osimertinib resistance for the sake of the improvement of survival and further achievement of precise medicine.
Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are the preferential options for advanced non-small cell lung cancer (NSCLC) patients harboring EGFR mutations. Osimertinib is a potent irreversible third-generation EGFR-TKI targeting EGFR mutations but has little effect on wild-type EGFR. In view of its remarkable efficacy and manageable safety, osimertinib was recommended as the standard first-line treatment for advanced or metastatic NSCLC patients with EGFR mutations. However, as the other EGFR-TKIs, osimertinib will inevitably develop acquired resistance, which limits its efficacy on the treatment of EGFR-mutated NSCLC patients. The etiology of triggering osimertinib resistance is complex including EGFR-dependent and EGFR-independent pathways, and different therapeutic strategies for the NSCLC patients with osimertinib resistance have been developed. Herein, we comprehensively summarized the resistance mechanisms of osimertinib and discuss in detail the potential therapeutic strategies for EGFR-mutated NSCLC patients suffering osimertinib resistance for the sake of the improvement of survival and further achievement of precise medicine. Keywords: Osimertinib, EGFR-TKIs, NSCLC, Resistance mechanisms, Therapeutic strategy, Targeted therapy, Chemotherapy, Immunotherapy, Precise medicine
Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are the preferential options for advanced non-small cell lung cancer (NSCLC) patients harboring EGFR mutations. Osimertinib is a potent irreversible third-generation EGFR-TKI targeting EGFR mutations but has little effect on wild-type EGFR. In view of its remarkable efficacy and manageable safety, osimertinib was recommended as the standard first-line treatment for advanced or metastatic NSCLC patients with EGFR mutations. However, as the other EGFR-TKIs, osimertinib will inevitably develop acquired resistance, which limits its efficacy on the treatment of EGFR-mutated NSCLC patients. The etiology of triggering osimertinib resistance is complex including EGFR-dependent and EGFR-independent pathways, and different therapeutic strategies for the NSCLC patients with osimertinib resistance have been developed. Herein, we comprehensively summarized the resistance mechanisms of osimertinib and discuss in detail the potential therapeutic strategies for EGFR-mutated NSCLC patients suffering osimertinib resistance for the sake of the improvement of survival and further achievement of precise medicine.Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are the preferential options for advanced non-small cell lung cancer (NSCLC) patients harboring EGFR mutations. Osimertinib is a potent irreversible third-generation EGFR-TKI targeting EGFR mutations but has little effect on wild-type EGFR. In view of its remarkable efficacy and manageable safety, osimertinib was recommended as the standard first-line treatment for advanced or metastatic NSCLC patients with EGFR mutations. However, as the other EGFR-TKIs, osimertinib will inevitably develop acquired resistance, which limits its efficacy on the treatment of EGFR-mutated NSCLC patients. The etiology of triggering osimertinib resistance is complex including EGFR-dependent and EGFR-independent pathways, and different therapeutic strategies for the NSCLC patients with osimertinib resistance have been developed. Herein, we comprehensively summarized the resistance mechanisms of osimertinib and discuss in detail the potential therapeutic strategies for EGFR-mutated NSCLC patients suffering osimertinib resistance for the sake of the improvement of survival and further achievement of precise medicine.
Abstract Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are the preferential options for advanced non-small cell lung cancer (NSCLC) patients harboring EGFR mutations. Osimertinib is a potent irreversible third-generation EGFR-TKI targeting EGFR mutations but has little effect on wild-type EGFR. In view of its remarkable efficacy and manageable safety, osimertinib was recommended as the standard first-line treatment for advanced or metastatic NSCLC patients with EGFR mutations. However, as the other EGFR-TKIs, osimertinib will inevitably develop acquired resistance, which limits its efficacy on the treatment of EGFR-mutated NSCLC patients. The etiology of triggering osimertinib resistance is complex including EGFR-dependent and EGFR-independent pathways, and different therapeutic strategies for the NSCLC patients with osimertinib resistance have been developed. Herein, we comprehensively summarized the resistance mechanisms of osimertinib and discuss in detail the potential therapeutic strategies for EGFR-mutated NSCLC patients suffering osimertinib resistance for the sake of the improvement of survival and further achievement of precise medicine.
ArticleNumber 173
Audience Academic
Author Fu, Liwu
Wang, Fang
Fu, Kai
Xie, Fachao
Author_xml – sequence: 1
  givenname: Kai
  surname: Fu
  fullname: Fu, Kai
– sequence: 2
  givenname: Fachao
  surname: Xie
  fullname: Xie, Fachao
– sequence: 3
  givenname: Fang
  surname: Wang
  fullname: Wang, Fang
– sequence: 4
  givenname: Liwu
  surname: Fu
  fullname: Fu, Liwu
BackLink https://www.ncbi.nlm.nih.gov/pubmed/36482474$$D View this record in MEDLINE/PubMed
BookMark eNp9kltr3DAQhU1JaS7tH-hDMRRKX5zqLvmlEEKSBgKFsu9iLMteLba1leSW_vvK2Vx2QykGWYy-c0YazmlxNPnJFsV7jM4xVuJLxBQxXiFCKoRpjSv2qjjBkotKSUKO9vbHxWmMG4QErgl6UxxTwRRhkp0U_WptA2ztnJwpYwqQbO9sLDsfyqub6x_VOKdca8vcu4ojDENpbF6GeepLA5OxodxCcnZKsfzt0rr00Y02JDe5pgw2upgW6m3xuoMh2ncP_7NidX21uvxW3X2_ub28uKsMr1mqqIWGE8MEqE50mBGBsFDQKGBMtLLmhILltu4wKNrUlBglW9Rw3kFHhaFnxe3OtvWw0dvgRgh_tAen7ws-9Bry3cxgtQApa6lIQ4EyYaChAlFrODBZM9XQ7PV157Wdm9G2Jj8xwHBgengyubXu_S9dS0oRVtng84NB8D9nG5MeXVymB5P1c9RE8gzS3C-jH1-gGz-HKU9qoXieAufsmeohP8BNnc99zWKqLySpGSNcLtT5P6j8tXZ0Jkeoc7l-IPi0J1hbGNI6-iFHwk_xEPywP5GnUTzGKQNqB5jgYwy208bl-GSffAU3aIz0kly9S67OydX3ydWLlLyQPrr_R_QXIufusA
CitedBy_id crossref_primary_10_1038_s41401_024_01427_0
crossref_primary_10_3390_cancers16112138
crossref_primary_10_37349_etat_2024_00228
crossref_primary_10_1016_j_phrs_2024_107123
crossref_primary_10_3389_fonc_2024_1274034
crossref_primary_10_1016_j_jep_2024_118586
crossref_primary_10_1016_j_jtho_2024_11_032
crossref_primary_10_1016_j_ijbiomac_2024_135992
crossref_primary_10_1016_j_phymed_2023_155099
crossref_primary_10_1016_j_cllc_2024_12_003
crossref_primary_10_1016_j_ejmech_2024_116273
crossref_primary_10_3390_ijms25031398
crossref_primary_10_1615_CritRevEukaryotGeneExpr_2024053662
crossref_primary_10_1007_s11523_023_00991_5
crossref_primary_10_3390_cancers16233996
crossref_primary_10_1016_j_jdcr_2024_08_032
crossref_primary_10_2174_0115680096345676241001081051
crossref_primary_10_1134_S1068162024040174
crossref_primary_10_1080_10408363_2024_2302116
crossref_primary_10_3389_fmolb_2025_1548810
crossref_primary_10_3390_ijms242115801
crossref_primary_10_1016_j_ijbiomac_2023_126413
crossref_primary_10_1016_j_pathol_2025_03_001
crossref_primary_10_1016_j_ejphar_2024_176484
crossref_primary_10_3389_fonc_2023_1177482
crossref_primary_10_3390_cancers16132490
crossref_primary_10_3390_cancers15245788
crossref_primary_10_1007_s12094_024_03494_5
crossref_primary_10_1016_j_phymed_2025_156593
crossref_primary_10_3892_ijmm_2023_5305
crossref_primary_10_3892_ol_2025_14938
crossref_primary_10_26508_lsa_202402625
crossref_primary_10_1186_s40001_024_02187_7
crossref_primary_10_25259_Cytojournal_49_2024
crossref_primary_10_3390_molecules30050976
crossref_primary_10_61186_ibj_4289
crossref_primary_10_1002_INMD_20240069
crossref_primary_10_1007_s12325_023_02680_1
crossref_primary_10_1002_2211_5463_13970
crossref_primary_10_3389_fcell_2024_1511190
crossref_primary_10_3390_cancers16111984
crossref_primary_10_1097_COC_0000000000001047
crossref_primary_10_1038_s41388_024_03096_z
crossref_primary_10_3390_cancers15030841
crossref_primary_10_1177_17588359241280689
crossref_primary_10_2147_DDDT_S490303
crossref_primary_10_3390_ijms25042382
crossref_primary_10_12998_wjcc_v12_i32_6543
crossref_primary_10_1016_j_ejphar_2024_176871
crossref_primary_10_1016_j_isci_2023_108711
crossref_primary_10_1016_j_jtocrr_2024_100686
crossref_primary_10_1038_s41467_024_52975_2
crossref_primary_10_23736_S2724_5985_23_03490_3
crossref_primary_10_1080_17476348_2025_2467338
crossref_primary_10_1021_acs_jmedchem_4c03168
crossref_primary_10_1158_0008_5472_CAN_24_0249
crossref_primary_10_3389_fonc_2024_1435537
crossref_primary_10_2174_0113816128263069231010111347
crossref_primary_10_1016_j_lungcan_2024_107815
crossref_primary_10_1016_j_cbi_2024_111055
crossref_primary_10_1038_s41419_024_06945_7
crossref_primary_10_1186_s12967_024_06064_z
crossref_primary_10_1155_2024_5437090
crossref_primary_10_3390_cancers16173063
crossref_primary_10_1200_JCO_23_02747
crossref_primary_10_18632_oncotarget_28569
crossref_primary_10_1016_j_lfs_2024_122614
crossref_primary_10_1016_j_heliyon_2023_e20300
crossref_primary_10_1016_j_bmc_2025_118146
crossref_primary_10_3390_ph17020210
crossref_primary_10_1002_advs_202411479
crossref_primary_10_1038_s41388_024_03220_z
crossref_primary_10_1177_11795549231205206
crossref_primary_10_1016_j_resinv_2023_09_006
crossref_primary_10_1186_s40164_024_00594_4
crossref_primary_10_1016_j_bmc_2024_117796
crossref_primary_10_3390_curroncol31080327
crossref_primary_10_1055_a_2305_2789
crossref_primary_10_1002_mc_23651
crossref_primary_10_1016_j_taap_2025_117280
crossref_primary_10_54097_0trsfx05
crossref_primary_10_22246_jikm_2024_45_6_1184
crossref_primary_10_1007_s12195_024_00822_1
crossref_primary_10_1200_PO_23_00677
crossref_primary_10_1002_2056_4538_70004
crossref_primary_10_1002_mog2_70011
crossref_primary_10_1007_s11033_024_09865_z
crossref_primary_10_2174_0929867330666230309143711
crossref_primary_10_1016_j_drup_2023_101002
crossref_primary_10_1016_j_eclinm_2024_102853
crossref_primary_10_1016_j_bbcan_2024_189108
crossref_primary_10_62347_TCEC1867
crossref_primary_10_1007_s00108_023_01651_6
crossref_primary_10_1186_s13045_024_01656_0
crossref_primary_10_3389_fphar_2024_1359403
crossref_primary_10_1097_MS9_0000000000002965
crossref_primary_10_3389_fonc_2023_1252652
crossref_primary_10_1038_s41598_025_85366_8
crossref_primary_10_1016_j_rechem_2024_101413
crossref_primary_10_1007_s10495_024_02052_2
crossref_primary_10_1186_s12885_024_12701_z
crossref_primary_10_1038_s41401_025_01511_z
crossref_primary_10_1177_10781552231184182
crossref_primary_10_1007_s12672_024_01552_6
crossref_primary_10_3390_receptors3040021
crossref_primary_10_1007_s10616_024_00673_8
crossref_primary_10_3390_cancers15215248
crossref_primary_10_62347_RLVZ6860
crossref_primary_10_1097_CAD_0000000000001624
crossref_primary_10_1016_j_ejphar_2024_177084
crossref_primary_10_1002_iub_2914
crossref_primary_10_1016_j_tranon_2023_101832
crossref_primary_10_1080_13543776_2024_2327307
crossref_primary_10_1097_CAD_0000000000001530
crossref_primary_10_1016_j_ejmech_2024_117140
crossref_primary_10_3389_fonc_2024_1470827
crossref_primary_10_54751_revistafoco_v17n12_029
crossref_primary_10_1172_jci_insight_186165
crossref_primary_10_3389_fonc_2024_1442237
crossref_primary_10_1080_1120009X_2024_2445909
crossref_primary_10_3389_fimmu_2023_1332057
crossref_primary_10_1186_s40164_024_00565_9
crossref_primary_10_1016_j_cyto_2024_156802
crossref_primary_10_1021_acs_analchem_4c06508
crossref_primary_10_3390_cells13050436
crossref_primary_10_1016_j_intimp_2023_111147
crossref_primary_10_1186_s12885_024_13168_8
crossref_primary_10_2174_0115672018278617231207051907
crossref_primary_10_1016_j_jbc_2024_107994
crossref_primary_10_7555_JBR_38_20240045
crossref_primary_10_1016_j_compbiomed_2024_108937
crossref_primary_10_1016_j_bcp_2024_116110
crossref_primary_10_1016_j_cej_2025_161305
crossref_primary_10_3390_curroncol31040146
crossref_primary_10_1007_s00262_024_03881_5
crossref_primary_10_1038_s41392_024_01899_w
crossref_primary_10_3390_cimb47010066
crossref_primary_10_3390_cancers16122205
crossref_primary_10_3390_curroncol31050182
crossref_primary_10_1001_jama_2024_10613
crossref_primary_10_1111_1759_7714_70025
crossref_primary_10_4155_fmc_2023_0243
Cites_doi 10.1016/j.annonc.2021.11.010
10.1016/j.ctrv.2018.02.006
10.1016/j.jtho.2019.11.005
10.1158/0008-5472.CAN-16-2359
10.1186/s12943-019-1112-1
10.1093/annonc/mdx703
10.1038/s41401-020-0457-8
10.1016/j.jtho.2019.07.018
10.1016/j.jtho.2019.06.002
10.1038/nm.3854
10.1093/annonc/mdw611
10.1016/j.jtho.2019.09.006
10.1200/JCO.21.00662
10.1016/j.jtho.2019.12.113
10.1056/NEJMoa1801005
10.1007/s11523-019-00669-x
10.1158/1535-7163.MCT-20-0229
10.1056/NEJMoa1612674
10.1111/1759-7714.13521
10.2165/00003495-200262150-00008
10.1007/s40265-015-0533-4
10.2217/fon-2021-0923
10.1056/NEJMoa2112431
10.1200/JCO.19.03123
10.1158/0008-5472.CAN-09-3106
10.1200/JCO.2009.22.0616
10.1200/JCO.1988.6.9.1474
10.1158/2159-8290.CD-20-0116
10.1016/j.jtho.2022.05.006
10.1158/0008-5472.CAN-20-2435
10.1038/s41392-022-00947-7
10.1002/cncr.32996
10.1093/annonc/mdz123
10.1016/j.humpath.2015.08.014
10.1016/j.lungcan.2019.10.014
10.1056/NEJMoa2027071
10.1093/gastro/goaa023
10.1016/j.jtho.2019.04.020
10.1158/1078-0432.CCR-17-1574
10.1016/j.jtho.2017.10.032
10.1016/S1470-2045(11)70184-X
10.1016/j.jtho.2017.02.014
10.1186/s13046-017-0653-7
10.1200/JCO.2007.14.8494
10.1016/j.jtho.2019.07.027
10.1093/annonc/mdz167
10.1158/2159-8290.CD-18-1022
10.1200/JCO.18.01585
10.1158/2159-8290.CD-21-0715
10.1016/j.jtho.2020.10.006
10.1001/jamaoncol.2020.6758
10.1007/s40265-021-01588-w
10.21037/atm.2019.04.37
10.1158/1078-0432.CCR-21-0765
10.1158/1538-7445.AM2022-CT184
10.1158/1538-7445.AM2022-3346
10.1080/15384047.2019.1617561
10.1016/S1470-2045(16)30508-3
10.2147/OTT.S300556
10.1001/jamaoncol.2020.0409
10.1016/S1470-2045(13)70604-1
10.1056/NEJMoa1606774
10.1016/S1470-2045(19)30785-5
10.1016/j.jtho.2018.02.005
10.1200/PO.18.00126
10.1200/JCO.2018.78.3118
10.1016/j.jtho.2019.05.040
10.1016/j.jtho.2019.09.198
10.1016/j.jtho.2021.10.024
10.1093/annonc/mdy275
10.1016/j.lungcan.2014.03.016
10.1093/emboj/19.13.3159
10.21037/tlcr-20-847
10.1200/JCO.2018.77.9363
10.1016/j.jbc.2021.100641
10.1016/S1470-2045(19)30504-2
10.1016/j.cllc.2021.06.006
10.1016/j.jtho.2018.12.021
10.1016/j.jtho.2021.04.011
10.1016/j.cllc.2019.12.002
10.1016/S0140-6736(03)12190-3
10.1016/S1470-2045(11)70393-X
10.1038/s41467-018-07078-0
10.1016/S2213-2600(17)30480-0
10.3390/cancers13010006
10.1200/JCO.19.00457
10.1093/annonc/mdz077
10.1007/s00432-020-03239-1
10.1016/j.jtho.2019.05.046
10.18632/oncotarget.7189
10.1016/j.lungcan.2020.06.003
10.1016/j.lungcan.2021.07.004
10.1016/j.jtho.2018.10.160
10.1016/S2213-2600(22)00168-0
10.1016/j.annonc.2021.06.004
10.1158/1535-7163.TARG-21-P230
10.1158/2159-8290.CD-18-0903
10.1186/s12943-020-01200-x
10.1158/0008-5472.CAN-15-2833
10.1016/S1470-2045(13)70355-3
10.1001/jamaoncol.2018.2969
10.1016/S1470-2045(22)00382-5
10.1056/NEJMoa1913662
10.1016/S1470-2045(09)70364-X
10.1200/JCO.2017.74.7576
10.1016/j.annonc.2020.01.013
10.1158/2159-8290.CD-14-0337
10.1016/j.jtho.2019.01.025
10.2147/OTT.S240775
10.1016/j.jtho.2019.02.001
10.1016/j.jtho.2017.08.006
10.1016/j.lungcan.2018.10.026
10.1016/S2213-2600(19)30084-0
10.1200/JCO.2012.44.2806
10.1016/j.jtho.2017.06.017
10.1016/j.jtho.2020.03.028
10.1016/S1470-2045(19)30167-6
10.1093/annonc/mdr003
10.1111/cas.14593
10.1158/1538-7445.AM2021-1262
10.1200/JCO.2017.73.9250
10.3390/cancers10080248
10.1200/JCO.21.02641
10.1016/j.jtho.2018.05.023
10.1007/s40265-021-01561-7
10.1158/1078-0432.CCR-14-2082
10.1016/S1470-2045(14)71173-8
10.1158/2159-8290.CD-NB2022-0053
10.1016/S1470-2045(14)70452-8
10.1158/1078-0432.CCR-17-2310
10.1007/s11523-019-00652-6
10.1097/JTO.0000000000000688
10.1158/0008-5472.CAN-14-3167
10.1016/S1470-2045(15)00121-7
10.2217/fon-2018-0626
10.1007/s40265-013-0050-2
10.1007/s40265-021-01533-x
10.2147/OTT.S298655
10.1056/NEJMoa0909530
10.1016/j.lungcan.2017.04.003
10.3322/caac.21654
10.1093/annonc/mdy424.064
10.1016/j.lungcan.2020.05.036
10.1056/NEJMoa1209124
10.1016/j.jtho.2017.02.020
10.1111/cas.15035
10.1016/j.jtho.2020.07.014
10.1200/JCO.2019.37.15_suppl.9051
10.1007/s40265-015-0537-0
10.21037/atm-22-2436
10.1016/j.jtho.2020.04.014
10.1200/JCO.21.02911
10.1038/s41467-018-08074-0
10.1016/j.jtho.2020.10.008
10.1038/ncomms14768
10.1016/j.canlet.2016.11.008
10.1093/annonc/mdx017
10.1038/s41698-020-0127-9
10.1016/j.lungcan.2019.05.024
10.1186/s12885-018-4075-5
10.1016/j.jtho.2017.07.017
10.1002/cam4.4336
10.1200/JCO.2016.72.1894
10.1158/1078-0432.CCR-18-1542
10.1093/annonc/mdz260.048
10.1016/S0962-8924(03)00104-1
10.3727/096504018X15344979253618
10.1001/jamaoncol.2017.4427
10.1016/j.cllc.2020.05.016
10.1158/1078-0432.CCR-18-1590
10.1093/annonc/mdx359
10.1016/j.jtho.2021.06.013
10.1200/JCO.19.01488
10.1158/1078-0432.CCR-15-1915
10.1158/1078-0432.CCR-19-3563
10.1016/S1470-2045(16)30033-X
10.1158/1078-0432.CCR-20-1690
10.1038/nature17960
10.1016/j.ejca.2021.02.019
10.1002/cncr.32809
10.1038/s41698-021-00208-w
10.1016/j.jtho.2021.09.014
10.1016/j.jtho.2019.01.015
10.1111/1759-7714.13255
10.1021/acs.jmedchem.2c00704
10.1038/s41698-021-00149-4
10.1158/1078-0432.CCR-18-0450
10.1016/j.lungcan.2017.07.002
10.18632/oncotarget.17913
10.1016/j.ccell.2021.07.005
10.1016/j.critrevonc.2017.07.003
10.1056/NEJMoa1810865
10.1186/s12885-019-5915-7
10.1093/annonc/mdx705
10.1158/1078-0432.CCR-15-0560
10.1158/1538-7445.AM2021-1467
10.1021/jm400822z
10.1158/1078-0432.CCR-19-2321
10.1158/1541-7786.MCR-19-0956
10.3390/cells9122596
10.1016/j.jtho.2018.04.007
10.1200/JCO.2016.70.3223
10.1038/s41416-019-0573-8
10.1016/S2213-2600(20)30455-0
10.1016/j.jtho.2018.05.024
10.1200/JCO.2018.78.7994
10.1016/j.lungcan.2020.12.039
10.1016/j.jtho.2018.12.038
10.1016/j.jtho.2019.04.013
10.1016/j.annonc.2020.06.017
10.1056/NEJMoa1713137
10.1126/science.1099314
10.1007/978-3-319-91442-8_18
10.1016/j.lungcan.2018.12.010
10.1200/JCO.2017.74.6065
10.1002/1878-0261.12682
10.1021/acs.jmedchem.9b01392
10.1016/S1470-2045(17)30608-3
10.1093/annonc/mdy424.063
10.1016/j.jtho.2021.11.025
10.1200/JCO.2016.71.9096
10.1200/JCO.2018.78.7697
10.1016/j.jtho.2019.07.016
10.1016/j.drup.2020.100741
10.1158/1535-7163.MCT-18-0591
10.1001/jamaoncol.2020.1260
10.1016/S1470-2045(15)00021-2
10.1093/annonc/mdz413.058
10.1038/s43018-022-00351-8
10.1093/annonc/mdv319
10.3389/fonc.2021.649843
10.1016/j.lungcan.2018.01.015
10.1016/j.lungcan.2017.07.006
10.1016/S0140-6736(15)01281-7
10.1158/1538-7445.AM2022-3328
10.1016/j.jtho.2018.03.035
10.1038/s43018-021-00195-8
10.1016/j.jtho.2020.06.018
10.1186/s12943-021-01307-9
10.1007/s11523-019-00644-6
ContentType Journal Article
Copyright 2022. The Author(s).
COPYRIGHT 2022 BioMed Central Ltd.
2022. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
The Author(s) 2022
Copyright_xml – notice: 2022. The Author(s).
– notice: COPYRIGHT 2022 BioMed Central Ltd.
– notice: 2022. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
– notice: The Author(s) 2022
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
3V.
7T5
7X7
7XB
88E
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BENPR
CCPQU
DWQXO
FYUFA
GHDGH
H94
K9.
M0S
M1P
PHGZM
PHGZT
PIMPY
PJZUB
PKEHL
PPXIY
PQEST
PQQKQ
PQUKI
PRINS
7X8
5PM
DOA
DOI 10.1186/s13045-022-01391-4
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
ProQuest Central (Corporate)
Immunology Abstracts
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central Essentials - QC
ProQuest Central
ProQuest One
ProQuest Central Korea
ProQuest Health Research Premium Collection
Health Research Premium Collection (Alumni)
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
ProQuest Health & Medical Collection
Medical Database
ProQuest Central Premium
ProQuest One Academic (New)
Publicly Available Content Database
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Publicly Available Content Database
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Central China
ProQuest Central
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
ProQuest Central Korea
Health & Medical Research Collection
AIDS and Cancer Research Abstracts
ProQuest Central (New)
ProQuest Medical Library (Alumni)
ProQuest One Academic Eastern Edition
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest Hospital Collection (Alumni)
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest One Academic UKI Edition
Immunology Abstracts
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList MEDLINE



MEDLINE - Academic
Publicly Available Content Database


CrossRef
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 4
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1756-8722
EndPage 32
ExternalDocumentID oai_doaj_org_article_6a779782b3a346cab3603ec5a47948b3
PMC9733018
A729442574
36482474
10_1186_s13045_022_01391_4
Genre Research Support, Non-U.S. Gov't
Journal Article
Review
GrantInformation_xml – fundername: ;
  grantid: 2020B1515120032; 2020B1515120032; 2020B1515120032; 2020B1515120032
– fundername: ;
  grantid: NO. 82073882; NO. 82073882; NO. 82073882; NO. 82073882
GroupedDBID ---
0R~
2WC
53G
5VS
7X7
88E
8FI
8FJ
AAFWJ
AAJSJ
AASML
AAYXX
ABDBF
ABUWG
ACGFS
ACIHN
ACPRK
ACUHS
ADBBV
ADRAZ
ADUKV
AEAQA
AENEX
AFKRA
AFPKN
AHBYD
AHMBA
AHYZX
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AMKLP
AMTXH
AOIJS
BAPOH
BAWUL
BCNDV
BENPR
BFQNJ
BMC
BPHCQ
BVXVI
C6C
CCPQU
CITATION
CS3
DIK
DU5
E3Z
EBD
EBLON
EBS
EMOBN
ESX
F5P
FYUFA
GROUPED_DOAJ
GX1
HMCUK
HYE
IAO
IEA
IHR
IHW
INH
INR
ITC
KQ8
M1P
M48
M~E
O5R
O5S
OK1
P2P
PGMZT
PHGZM
PHGZT
PIMPY
PQQKQ
PROAC
PSQYO
RBZ
ROL
RPM
RSV
SMD
SOJ
SV3
TR2
TUS
UKHRP
~8M
-5E
-5G
-A0
-BR
3V.
ACRMQ
ADINQ
C24
CGR
CUY
CVF
ECM
EIF
NPM
PMFND
7T5
7XB
8FK
AZQEC
DWQXO
H94
K9.
PJZUB
PKEHL
PPXIY
PQEST
PQUKI
PRINS
7X8
5PM
PUEGO
ID FETCH-LOGICAL-c594t-3eab52c46a8f6f14260168ab8a446d79523ae5e9f1a83b932c87d0b55faf36c3
IEDL.DBID DOA
ISSN 1756-8722
IngestDate Wed Aug 27 01:29:35 EDT 2025
Thu Aug 21 18:38:49 EDT 2025
Mon Jul 21 11:57:34 EDT 2025
Fri Jul 25 05:48:33 EDT 2025
Tue Jun 17 20:50:04 EDT 2025
Tue Jun 10 20:35:21 EDT 2025
Thu May 22 21:24:14 EDT 2025
Thu Jan 02 22:54:29 EST 2025
Thu Apr 24 23:16:24 EDT 2025
Tue Jul 01 04:23:17 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Keywords Chemotherapy
NSCLC
Targeted therapy
Immunotherapy
EGFR-TKIs
Precise medicine
Osimertinib
Therapeutic strategy
Resistance mechanisms
Language English
License 2022. The Author(s).
Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c594t-3eab52c46a8f6f14260168ab8a446d79523ae5e9f1a83b932c87d0b55faf36c3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Review-3
content type line 23
OpenAccessLink https://doaj.org/article/6a779782b3a346cab3603ec5a47948b3
PMID 36482474
PQID 2755601554
PQPubID 54946
PageCount 32
ParticipantIDs doaj_primary_oai_doaj_org_article_6a779782b3a346cab3603ec5a47948b3
pubmedcentral_primary_oai_pubmedcentral_nih_gov_9733018
proquest_miscellaneous_2753303479
proquest_journals_2755601554
gale_infotracmisc_A729442574
gale_infotracacademiconefile_A729442574
gale_healthsolutions_A729442574
pubmed_primary_36482474
crossref_citationtrail_10_1186_s13045_022_01391_4
crossref_primary_10_1186_s13045_022_01391_4
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2022-12-08
PublicationDateYYYYMMDD 2022-12-08
PublicationDate_xml – month: 12
  year: 2022
  text: 2022-12-08
  day: 08
PublicationDecade 2020
PublicationPlace England
PublicationPlace_xml – name: England
– name: London
PublicationTitle Journal of hematology and oncology
PublicationTitleAlternate J Hematol Oncol
PublicationYear 2022
Publisher BioMed Central Ltd
BioMed Central
BMC
Publisher_xml – name: BioMed Central Ltd
– name: BioMed Central
– name: BMC
References J Neijssen (1391_CR207) 2021; 296
N Peled (1391_CR229) 2022; 4
Y Wang (1391_CR133) 2020; 146
JM Sands (1391_CR224) 2019; 37
P Meng (1391_CR153) 2020; 146
C Conti (1391_CR124) 2021; 81
M Reck (1391_CR192) 2019; 7
Q Su (1391_CR161) 2020; 63
S Park (1391_CR234) 2020; 31
A Oztan (1391_CR73) 2017; 111
CC Hsu (1391_CR80) 2020; 15
JCH Yang (1391_CR231) 2020; 38
GR Oxnard (1391_CR63) 2018; 4
LV Sequist (1391_CR40) 2013; 31
S La Monica (1391_CR147) 2019; 14
I Dagogo-Jack (1391_CR143) 2019; 14
E Miyauchi (1391_CR172) 2022
S Wang (1391_CR120) 2017; 385
MJ Ahn (1391_CR244) 2019; 20
A Leonetti (1391_CR53) 2019; 121
M Stepanova (1391_CR60) 2019; 30
LV Sequist (1391_CR32) 2008; 26
HA Yu (1391_CR198) 2020; 6
S Nukaga (1391_CR75) 2017; 77
J Lee (1391_CR65) 2020; 126
A Lisberg (1391_CR179) 2018; 13
SL Greig (1391_CR21) 2016; 76
K Kashima (1391_CR123) 2020; 19
Y Mu (1391_CR166) 2019; 14
CC Lin (1391_CR27) 2018; 6
KS Thress (1391_CR28) 2015; 21
A Inoue (1391_CR38) 2003; 361
BT Li (1391_CR218) 2022; 386
Z Song (1391_CR118) 2022; 10
Y Cheng (1391_CR3) 2021; 2
L Zeng (1391_CR88) 2018; 13
GR Oxnard (1391_CR134) 2020; 31
D Rangachari (1391_CR98) 2019; 14
MJ Niederst (1391_CR108) 2015; 21
HS Li (1391_CR102) 2021; 11
JK Lee (1391_CR95) 2017; 35
E Shum (1391_CR129) 2022; 82
JC Yang (1391_CR182) 2019; 14
M Ribeiro (1391_CR156) 2021; 5
TM Kim (1391_CR83) 2015; 10
D Hayakawa (1391_CR84) 2020; 11
U Malapelle (1391_CR15) 2018; 211
S Park (1391_CR93) 2019; 134
Z Wu (1391_CR81) 2015; 46
F Barlesi (1391_CR237) 2011; 22
JC Soria (1391_CR169) 2015; 16
D Planchard (1391_CR25) 2018; 29
H Yoshida (1391_CR174) 2018; 13
S Lu (1391_CR47) 2022
S Zhao (1391_CR77) 2019; 128
SS Ramalingam (1391_CR23) 2018; 36
S La Monica (1391_CR163) 2020; 13
H Kenmotsu (1391_CR199) 2022; 17
R Zhou (1391_CR116) 2021; 14
Q Zhang (1391_CR69) 2018; 13
ZF Wang (1391_CR12) 2018; 18
JC Yang (1391_CR41) 2015; 16
K Zhang (1391_CR141) 2019; 27
SI Ou (1391_CR86) 2017; 111
Q Zhou (1391_CR197) 2021; 39
Y Mu (1391_CR62) 2020; 146
Z Xie (1391_CR167) 2019; 20
T Reungwetwattana (1391_CR228) 2018
J Lee (1391_CR233) 2020; 15
N Nogami (1391_CR193) 2022; 17
CR Culy (1391_CR33) 2002; 62
M Offin (1391_CR96) 2019; 14
CA Eberlein (1391_CR148) 2015; 75
X Zhang (1391_CR159) 2021; 81
M Reck (1391_CR175) 2016; 375
YK Shi (1391_CR37) 2017; 28
CK Lee (1391_CR177) 2018; 4
V Fuchs (1391_CR79) 2021; 153
TSK Mok (1391_CR170) 2017; 35
H Akamatsu (1391_CR200) 2021; 7
W Ji (1391_CR164) 2020; 9
SS Ramalingam (1391_CR43) 2014; 15
BC Cho (1391_CR212) 2022; 18
D Westover (1391_CR9) 2018; 29
CG Kim (1391_CR180) 2019; 30
AJ Schoenfeld (1391_CR94) 2020; 26
SG Wu (1391_CR11) 2016; 7
SS Ramalingam (1391_CR57) 2018; 29
A Ballantyne (1391_CR213) 2013; 73
MM Zheng (1391_CR239) 2021; 16
K Park (1391_CR210) 2021; 39
C Zhou (1391_CR35) 2011; 12
X Le (1391_CR56) 2018; 24
S Dhillon (1391_CR51) 2021; 81
Z Wang (1391_CR110) 2017; 12
H Ding (1391_CR154) 2020; 13
YL Wu (1391_CR227) 2018; 36
M Maemondo (1391_CR5) 2010; 362
W Fang (1391_CR103) 2020; 15
MS Eno (1391_CR126) 2022; 65
J Remon (1391_CR240) 2017; 28
SI Ou (1391_CR68) 2017; 108
M Nishino (1391_CR100) 2018; 126
BC Cho (1391_CR245) 2022; 17
A Nishiyama (1391_CR29) 2020; 111
YY Syed (1391_CR211) 2021; 81
U Testa (1391_CR2) 2018; 10
L Tavera (1391_CR125) 2022; 82
JW Carlisle (1391_CR18) 2019; 15
AJ Schoenfeld (1391_CR59) 2020; 15
D Romaniello (1391_CR203) 2018; 24
M Vojnic (1391_CR144) 2019; 14
N Marcoux (1391_CR168) 2019; 37
N Chic (1391_CR99) 2017; 12
YL Wu (1391_CR8) 2017; 18
P Shi (1391_CR149) 2017; 23
S Wu (1391_CR76) 2021; 20
TJ Jin (1391_CR130) 2022; 82
C To (1391_CR121) 2019; 9
JH Strickler (1391_CR222) 2018; 36
HR Park (1391_CR158) 2021; 16
J Liu (1391_CR90) 2019; 14
VA Papadimitrakopoulou (1391_CR58) 2018; 29
X Wang (1391_CR181) 2020; 19
SM Lim (1391_CR127) 2021; 81
LV Sequist (1391_CR135) 2020; 21
M Zhong (1391_CR242) 2020; 8
Y Hosomi (1391_CR171) 2020; 38
U Batra (1391_CR87) 2020; 21
MG Terp (1391_CR138) 2021; 5
Y Wang (1391_CR114) 2020; 15
MA Olayioye (1391_CR30) 2000; 19
TC Lam (1391_CR194) 2021; 159
HA Yu (1391_CR202) 2021; 27
Z Fu (1391_CR214) 2022; 7
X Yang (1391_CR107) 2020; 21
C To (1391_CR122) 2022; 3
K Nakatani (1391_CR146) 2019; 18
S La Monica (1391_CR220) 2017; 36
T Manabe (1391_CR139) 2020; 18
B Besse (1391_CR236) 2015; 21
YL Wu (1391_CR230) 2020; 383
Z Piotrowska (1391_CR89) 2018; 8
S Lu (1391_CR49) 2022; 17
Y Yang (1391_CR115) 2021; 10
ED Deeks (1391_CR50) 2021; 81
M Rosário (1391_CR78) 2003; 13
Q Qin (1391_CR162) 2020; 11
K Uchibori (1391_CR112) 2017; 8
SS Ramalingam (1391_CR46) 2020; 382
AW Nelson (1391_CR142) 2019; 14
H West (1391_CR191) 2019; 20
X Le (1391_CR196) 2021; 16
Y Huang (1391_CR92) 2019; 14
J Mazieres (1391_CR178) 2019; 30
C Yang (1391_CR241) 2021; 54
S Arulananda (1391_CR109) 2017; 12
L Zhang (1391_CR157) 2020; 19
N Thatcher (1391_CR205) 2015; 16
RA Ward (1391_CR16) 2013; 56
M Offin (1391_CR85) 2018; 2
X Wang (1391_CR113) 2019; 14
JJ Lin (1391_CR145) 2020; 4
O Gautschi (1391_CR136) 2020; 15
SL Moores (1391_CR208) 2016; 76
S Verma (1391_CR215) 2012; 367
D Spigel (1391_CR128) 2021; 20
HA Yu (1391_CR165) 2021; 22
MA Socinski (1391_CR235) 2009; 27
Y Shi (1391_CR36) 2013; 14
J Fassunke (1391_CR74) 2018; 9
L Paz-Ares (1391_CR42) 2017; 28
GH Liu (1391_CR4) 2022; 3
F Zhou (1391_CR155) 2020; 139
W Fang (1391_CR204) 2019; 14
Z Yang (1391_CR66) 2018; 24
L Gandhi (1391_CR186) 2018; 378
C Zhou (1391_CR185) 2021; 16
J Yun (1391_CR209) 2020; 10
JC Soria (1391_CR22) 2018; 378
AJ Piper-Vallillo (1391_CR64) 2020
RS Heist (1391_CR225) 2017; 35
TS Mok (1391_CR45) 2017; 376
Y Zhao (1391_CR117) 2021; 14
MJ Ahn (1391_CR232) 2020; 15
DR Camidge (1391_CR223) 2021; 27
Y Shi (1391_CR48) 2022; 10
N Okura (1391_CR140) 2020; 26
A Russo (1391_CR17) 2017; 117
JL Kuiper (1391_CR10) 2014; 85
Z Yang (1391_CR70) 2019; 14
S Sugawara (1391_CR189) 2021; 32
1391_CR219
K Tanaka (1391_CR173) 2021; 149
K Park (1391_CR7) 2016; 17
D Planchard (1391_CR26) 2015; 26
RS Herbst (1391_CR176) 2016; 387
L Paz-Ares (1391_CR187) 2018; 379
IM Goldstein (1391_CR238) 2020; 2
K Hotta (1391_CR216) 2018; 13
A Bearz (1391_CR91) 2017; 12
RA Soo (1391_CR201) 2022; 33
JC Yang (1391_CR20) 2017; 35
TS Mok (1391_CR44) 2018; 36
L Lin (1391_CR101) 2020; 10
J Liu (1391_CR106) 2019; 19
L Deng (1391_CR131) 2018; 13
Y Liu (1391_CR72) 2018; 118
R Rosell (1391_CR34) 2012; 13
G Goss (1391_CR19) 2016; 17
A Quintanal-Villalonga (1391_CR137) 2019; 14
H Taniguchi (1391_CR82) 2019; 10
R Han (1391_CR160) 2020; 14
D Zheng (1391_CR67) 2017; 8
Y Shi (1391_CR243) 2021; 9
L Ma (1391_CR71) 2019; 7
C Ricordel (1391_CR52) 2018; 29
DH Enrico (1391_CR61) 2019; 30
XM Jiang (1391_CR97) 2021; 42
PA Jänne (1391_CR221) 2022; 12
S Lu (1391_CR195) 2022; 23
S Ortiz-Cuaran (1391_CR151) 2016; 22
J Gu (1391_CR150) 2020; 126
O Arrieta (1391_CR190) 2020; 6
N Hanna (1391_CR24) 2017; 35
R Jotte (1391_CR188) 2020; 15
RL Siegel (1391_CR1) 2021; 71
ER York (1391_CR132) 2017; 12
A Passaro (1391_CR55) 2021; 2
T Mitsudomi (1391_CR6) 2010; 11
Y Li (1391_CR104) 2020; 9
ML Sos (1391_CR13) 2010; 70
YL Wu (1391_CR39) 2014; 15
KP Garnock-Jones (1391_CR206) 2016; 76
Z Zhou (1391_CR111) 2019; 14
S Peters (1391_CR217) 2019; 25
DA Cross (1391_CR14) 2014; 4
Y Jia (1391_CR119) 2016; 534
Y Yang (1391_CR184) 2020; 15
SM Lim (1391_CR54) 2018; 65
K Fukuda (1391_CR152) 2021; 112
JG Paez (1391_CR31) 2004; 304
W Fang (1391_CR105) 2019; 14
JB Sørensen (1391_CR226) 1988; 6
AJ Schoenfeld (1391_CR183) 2019; 30
References_xml – volume: 33
  start-page: 181
  issue: 2
  year: 2022
  ident: 1391_CR201
  publication-title: Ann Oncol
  doi: 10.1016/j.annonc.2021.11.010
– volume: 65
  start-page: 1
  year: 2018
  ident: 1391_CR54
  publication-title: Cancer Treat Rev
  doi: 10.1016/j.ctrv.2018.02.006
– volume: 15
  start-page: 18
  issue: 1
  year: 2020
  ident: 1391_CR59
  publication-title: J Thorac Oncol
  doi: 10.1016/j.jtho.2019.11.005
– volume: 77
  start-page: 2078
  issue: 8
  year: 2017
  ident: 1391_CR75
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-16-2359
– volume: 19
  start-page: 10
  issue: 1
  year: 2020
  ident: 1391_CR157
  publication-title: Mol Cancer
  doi: 10.1186/s12943-019-1112-1
– volume: 29
  start-page: i10
  issue: suppl_1
  year: 2018
  ident: 1391_CR9
  publication-title: Ann Oncol
  doi: 10.1093/annonc/mdx703
– volume: 42
  start-page: 451
  issue: 3
  year: 2021
  ident: 1391_CR97
  publication-title: Acta Pharmacol Sin
  doi: 10.1038/s41401-020-0457-8
– volume: 14
  start-page: e274
  issue: 12
  year: 2019
  ident: 1391_CR105
  publication-title: J Thorac Oncol
  doi: 10.1016/j.jtho.2019.07.018
– volume: 14
  start-page: 1784
  issue: 10
  year: 2019
  ident: 1391_CR96
  publication-title: J Thorac Oncol
  doi: 10.1016/j.jtho.2019.06.002
– volume: 21
  start-page: 560
  issue: 6
  year: 2015
  ident: 1391_CR28
  publication-title: Nat Med
  doi: 10.1038/nm.3854
– volume: 28
  start-page: 270
  issue: 2
  year: 2017
  ident: 1391_CR42
  publication-title: Ann Oncol
  doi: 10.1093/annonc/mdw611
– volume: 15
  start-page: 50
  issue: 1
  year: 2020
  ident: 1391_CR80
  publication-title: J Thorac Oncol
  doi: 10.1016/j.jtho.2019.09.006
– volume: 39
  start-page: 3391
  issue: 30
  year: 2021
  ident: 1391_CR210
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.21.00662
– volume: 15
  start-page: 637
  issue: 4
  year: 2020
  ident: 1391_CR232
  publication-title: J Thorac Oncol
  doi: 10.1016/j.jtho.2019.12.113
– volume: 378
  start-page: 2078
  issue: 22
  year: 2018
  ident: 1391_CR186
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa1801005
– volume: 14
  start-page: 619
  issue: 5
  year: 2019
  ident: 1391_CR147
  publication-title: Target Oncol
  doi: 10.1007/s11523-019-00669-x
– volume: 19
  start-page: 2288
  issue: 11
  year: 2020
  ident: 1391_CR123
  publication-title: Mol Cancer Ther
  doi: 10.1158/1535-7163.MCT-20-0229
– volume: 376
  start-page: 629
  issue: 7
  year: 2017
  ident: 1391_CR45
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa1612674
– volume: 11
  start-page: 2389
  issue: 9
  year: 2020
  ident: 1391_CR162
  publication-title: Thorac Cancer
  doi: 10.1111/1759-7714.13521
– volume: 62
  start-page: 2237
  issue: 15
  year: 2002
  ident: 1391_CR33
  publication-title: Drugs
  doi: 10.2165/00003495-200262150-00008
– volume: 76
  start-page: 263
  issue: 2
  year: 2016
  ident: 1391_CR21
  publication-title: Drugs
  doi: 10.1007/s40265-015-0533-4
– volume: 18
  start-page: 639
  issue: 6
  year: 2022
  ident: 1391_CR212
  publication-title: Future Oncol
  doi: 10.2217/fon-2021-0923
– volume: 386
  start-page: 241
  issue: 3
  year: 2022
  ident: 1391_CR218
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa2112431
– year: 2020
  ident: 1391_CR64
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.19.03123
– volume: 70
  start-page: 868
  issue: 3
  year: 2010
  ident: 1391_CR13
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-09-3106
– volume: 27
  start-page: 5255
  issue: 31
  year: 2009
  ident: 1391_CR235
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2009.22.0616
– volume: 6
  start-page: 1474
  issue: 9
  year: 1988
  ident: 1391_CR226
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.1988.6.9.1474
– volume: 10
  start-page: 1194
  issue: 8
  year: 2020
  ident: 1391_CR209
  publication-title: Cancer Discov
  doi: 10.1158/2159-8290.CD-20-0116
– volume: 17
  start-page: 1098
  issue: 9
  year: 2022
  ident: 1391_CR199
  publication-title: J Thorac Oncol
  doi: 10.1016/j.jtho.2022.05.006
– volume: 81
  start-page: 3051
  issue: 11
  year: 2021
  ident: 1391_CR159
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-20-2435
– volume: 7
  start-page: 93
  issue: 1
  year: 2022
  ident: 1391_CR214
  publication-title: Signal Transduct Target Ther
  doi: 10.1038/s41392-022-00947-7
– volume: 126
  start-page: 3788
  issue: 16
  year: 2020
  ident: 1391_CR150
  publication-title: Cancer
  doi: 10.1002/cncr.32996
– volume: 30
  start-page: 1104
  issue: 7
  year: 2019
  ident: 1391_CR180
  publication-title: Ann Oncol
  doi: 10.1093/annonc/mdz123
– volume: 46
  start-page: 1935
  issue: 12
  year: 2015
  ident: 1391_CR81
  publication-title: Hum Pathol
  doi: 10.1016/j.humpath.2015.08.014
– volume: 139
  start-page: 219
  year: 2020
  ident: 1391_CR155
  publication-title: Lung Cancer
  doi: 10.1016/j.lungcan.2019.10.014
– volume: 383
  start-page: 1711
  issue: 18
  year: 2020
  ident: 1391_CR230
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa2027071
– volume: 8
  start-page: 224
  issue: 3
  year: 2020
  ident: 1391_CR242
  publication-title: Gastroenterol Rep (Oxf)
  doi: 10.1093/gastro/goaa023
– volume: 14
  start-page: e157
  issue: 8
  year: 2019
  ident: 1391_CR111
  publication-title: J Thorac Oncol
  doi: 10.1016/j.jtho.2019.04.020
– volume: 23
  start-page: 6567
  issue: 21
  year: 2017
  ident: 1391_CR149
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-17-1574
– volume: 13
  start-page: 273
  issue: 2
  year: 2018
  ident: 1391_CR216
  publication-title: J Thorac Oncol
  doi: 10.1016/j.jtho.2017.10.032
– volume: 12
  start-page: 735
  issue: 8
  year: 2011
  ident: 1391_CR35
  publication-title: Lancet Oncol
  doi: 10.1016/S1470-2045(11)70184-X
– volume: 12
  start-page: e78
  issue: 6
  year: 2017
  ident: 1391_CR99
  publication-title: J Thorac Oncol
  doi: 10.1016/j.jtho.2017.02.014
– volume: 36
  start-page: 174
  issue: 1
  year: 2017
  ident: 1391_CR220
  publication-title: J Exp Clin Cancer Res
  doi: 10.1186/s13046-017-0653-7
– volume: 26
  start-page: 2442
  issue: 15
  year: 2008
  ident: 1391_CR32
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2007.14.8494
– volume: 15
  start-page: e13
  issue: 1
  year: 2020
  ident: 1391_CR136
  publication-title: J Thorac Oncol
  doi: 10.1016/j.jtho.2019.07.027
– volume: 30
  start-page: 1321
  issue: 8
  year: 2019
  ident: 1391_CR178
  publication-title: Ann Oncol
  doi: 10.1093/annonc/mdz167
– volume: 8
  start-page: 1529
  issue: 12
  year: 2018
  ident: 1391_CR89
  publication-title: Cancer Discov
  doi: 10.1158/2159-8290.CD-18-1022
– volume: 37
  start-page: 278
  issue: 4
  year: 2019
  ident: 1391_CR168
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.18.01585
– volume: 12
  start-page: 74
  issue: 1
  year: 2022
  ident: 1391_CR221
  publication-title: Cancer Discov
  doi: 10.1158/2159-8290.CD-21-0715
– volume: 16
  start-page: 205
  issue: 2
  year: 2021
  ident: 1391_CR196
  publication-title: J Thorac Oncol
  doi: 10.1016/j.jtho.2020.10.006
– volume: 7
  start-page: 386
  issue: 3
  year: 2021
  ident: 1391_CR200
  publication-title: JAMA Oncol
  doi: 10.1001/jamaoncol.2020.6758
– volume: 81
  start-page: 1775
  issue: 15
  year: 2021
  ident: 1391_CR50
  publication-title: Drugs
  doi: 10.1007/s40265-021-01588-w
– volume: 7
  start-page: 207
  issue: 9
  year: 2019
  ident: 1391_CR71
  publication-title: Ann Transl Med
  doi: 10.21037/atm.2019.04.37
– volume: 27
  start-page: 5781
  issue: 21
  year: 2021
  ident: 1391_CR223
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-21-0765
– volume: 82
  start-page: CT184
  issue: 12
  year: 2022
  ident: 1391_CR129
  publication-title: Cancer Res
  doi: 10.1158/1538-7445.AM2022-CT184
– volume: 82
  start-page: 3346
  issue: 12_Supplement
  year: 2022
  ident: 1391_CR130
  publication-title: Cancer Res
  doi: 10.1158/1538-7445.AM2022-3346
– volume: 20
  start-page: 1172
  issue: 9
  year: 2019
  ident: 1391_CR167
  publication-title: Cancer Biol Ther
  doi: 10.1080/15384047.2019.1617561
– volume: 17
  start-page: 1643
  issue: 12
  year: 2016
  ident: 1391_CR19
  publication-title: Lancet Oncol
  doi: 10.1016/S1470-2045(16)30508-3
– volume: 14
  start-page: 3063
  year: 2021
  ident: 1391_CR117
  publication-title: Onco Targets Ther
  doi: 10.2147/OTT.S300556
– volume: 6
  start-page: 856
  issue: 6
  year: 2020
  ident: 1391_CR190
  publication-title: JAMA Oncol
  doi: 10.1001/jamaoncol.2020.0409
– volume: 15
  start-page: 213
  issue: 2
  year: 2014
  ident: 1391_CR39
  publication-title: Lancet Oncol
  doi: 10.1016/S1470-2045(13)70604-1
– volume: 375
  start-page: 1823
  issue: 19
  year: 2016
  ident: 1391_CR175
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa1606774
– volume: 21
  start-page: 373
  issue: 3
  year: 2020
  ident: 1391_CR135
  publication-title: Lancet Oncol
  doi: 10.1016/S1470-2045(19)30785-5
– volume: 13
  start-page: e114
  issue: 7
  year: 2018
  ident: 1391_CR88
  publication-title: J Thorac Oncol
  doi: 10.1016/j.jtho.2018.02.005
– volume: 2
  start-page: 1
  year: 2018
  ident: 1391_CR85
  publication-title: JCO Precis Oncol
  doi: 10.1200/PO.18.00126
– year: 2018
  ident: 1391_CR228
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2018.78.3118
– volume: 14
  start-page: e236
  issue: 10
  year: 2019
  ident: 1391_CR92
  publication-title: J Thorac Oncol
  doi: 10.1016/j.jtho.2019.05.040
– volume: 15
  start-page: e36
  issue: 3
  year: 2020
  ident: 1391_CR103
  publication-title: J Thorac Oncol
  doi: 10.1016/j.jtho.2019.09.198
– volume: 17
  start-page: 411
  issue: 3
  year: 2022
  ident: 1391_CR49
  publication-title: J Thorac Oncol
  doi: 10.1016/j.jtho.2021.10.024
– volume: 29
  start-page: iv192
  issue: Suppl 4
  year: 2018
  ident: 1391_CR25
  publication-title: Ann Oncol
  doi: 10.1093/annonc/mdy275
– volume: 85
  start-page: 19
  issue: 1
  year: 2014
  ident: 1391_CR10
  publication-title: Lung Cancer
  doi: 10.1016/j.lungcan.2014.03.016
– volume: 19
  start-page: 3159
  issue: 13
  year: 2000
  ident: 1391_CR30
  publication-title: Embo j
  doi: 10.1093/emboj/19.13.3159
– volume: 9
  start-page: 2188
  issue: 5
  year: 2020
  ident: 1391_CR104
  publication-title: Transl Lung Cancer Res
  doi: 10.21037/tlcr-20-847
– volume: 36
  start-page: 2702
  issue: 26
  year: 2018
  ident: 1391_CR227
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2018.77.9363
– volume: 296
  year: 2021
  ident: 1391_CR207
  publication-title: J Biol Chem
  doi: 10.1016/j.jbc.2021.100641
– volume: 20
  start-page: 1681
  issue: 12
  year: 2019
  ident: 1391_CR244
  publication-title: Lancet Oncol
  doi: 10.1016/S1470-2045(19)30504-2
– volume: 22
  start-page: 601
  issue: 6
  year: 2021
  ident: 1391_CR165
  publication-title: Clin Lung Cancer
  doi: 10.1016/j.cllc.2021.06.006
– volume: 14
  start-page: 641
  issue: 4
  year: 2019
  ident: 1391_CR137
  publication-title: J Thorac Oncol
  doi: 10.1016/j.jtho.2018.12.021
– volume: 16
  start-page: 1501
  issue: 9
  year: 2021
  ident: 1391_CR185
  publication-title: J Thorac Oncol
  doi: 10.1016/j.jtho.2021.04.011
– volume: 21
  start-page: e258
  issue: 4
  year: 2020
  ident: 1391_CR107
  publication-title: Clin Lung Cancer
  doi: 10.1016/j.cllc.2019.12.002
– volume: 361
  start-page: 137
  issue: 9352
  year: 2003
  ident: 1391_CR38
  publication-title: Lancet
  doi: 10.1016/S0140-6736(03)12190-3
– volume: 13
  start-page: 239
  issue: 3
  year: 2012
  ident: 1391_CR34
  publication-title: Lancet Oncol
  doi: 10.1016/S1470-2045(11)70393-X
– volume: 9
  start-page: 4655
  issue: 1
  year: 2018
  ident: 1391_CR74
  publication-title: Nat Commun
  doi: 10.1038/s41467-018-07078-0
– volume: 6
  start-page: 107
  issue: 2
  year: 2018
  ident: 1391_CR27
  publication-title: Lancet Respir Med
  doi: 10.1016/S2213-2600(17)30480-0
– volume: 13
  start-page: 6
  issue: 1
  year: 2020
  ident: 1391_CR163
  publication-title: Cancers (Basel)
  doi: 10.3390/cancers13010006
– volume: 38
  start-page: 538
  issue: 6
  year: 2020
  ident: 1391_CR231
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.19.00457
– volume: 30
  start-page: 839
  issue: 5
  year: 2019
  ident: 1391_CR183
  publication-title: Ann Oncol
  doi: 10.1093/annonc/mdz077
– volume: 146
  start-page: 2427
  issue: 9
  year: 2020
  ident: 1391_CR62
  publication-title: J Cancer Res Clin Oncol
  doi: 10.1007/s00432-020-03239-1
– volume: 14
  start-page: e226
  issue: 10
  year: 2019
  ident: 1391_CR143
  publication-title: J Thorac Oncol
  doi: 10.1016/j.jtho.2019.05.046
– volume: 7
  start-page: 12404
  issue: 11
  year: 2016
  ident: 1391_CR11
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.7189
– volume: 146
  start-page: 165
  year: 2020
  ident: 1391_CR133
  publication-title: Lung Cancer
  doi: 10.1016/j.lungcan.2020.06.003
– volume: 159
  start-page: 18
  year: 2021
  ident: 1391_CR194
  publication-title: Lung Cancer
  doi: 10.1016/j.lungcan.2021.07.004
– volume: 14
  start-page: e27
  issue: 2
  year: 2019
  ident: 1391_CR142
  publication-title: J Thorac Oncol
  doi: 10.1016/j.jtho.2018.10.160
– volume: 10
  start-page: 1019
  year: 2022
  ident: 1391_CR48
  publication-title: Lancet Respir Med
  doi: 10.1016/S2213-2600(22)00168-0
– volume: 32
  start-page: 1137
  issue: 9
  year: 2021
  ident: 1391_CR189
  publication-title: Ann Oncol
  doi: 10.1016/j.annonc.2021.06.004
– volume: 20
  start-page: 30
  issue: 12_Supplement
  year: 2021
  ident: 1391_CR128
  publication-title: Mol Cancer Ther
  doi: 10.1158/1535-7163.TARG-21-P230
– volume: 9
  start-page: 926
  issue: 7
  year: 2019
  ident: 1391_CR121
  publication-title: Cancer Discov
  doi: 10.1158/2159-8290.CD-18-0903
– volume: 19
  start-page: 81
  issue: 1
  year: 2020
  ident: 1391_CR181
  publication-title: Mol Cancer
  doi: 10.1186/s12943-020-01200-x
– volume: 76
  start-page: 3942
  issue: 13
  year: 2016
  ident: 1391_CR208
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-15-2833
– volume: 14
  start-page: 953
  issue: 10
  year: 2013
  ident: 1391_CR36
  publication-title: Lancet Oncol
  doi: 10.1016/S1470-2045(13)70355-3
– volume: 4
  start-page: 1527
  issue: 11
  year: 2018
  ident: 1391_CR63
  publication-title: JAMA Oncol
  doi: 10.1001/jamaoncol.2018.2969
– volume: 23
  start-page: 1167
  issue: 9
  year: 2022
  ident: 1391_CR195
  publication-title: Lancet Oncol
  doi: 10.1016/S1470-2045(22)00382-5
– volume: 382
  start-page: 41
  issue: 1
  year: 2020
  ident: 1391_CR46
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa1913662
– volume: 11
  start-page: 121
  issue: 2
  year: 2010
  ident: 1391_CR6
  publication-title: Lancet Oncol
  doi: 10.1016/S1470-2045(09)70364-X
– volume: 36
  start-page: 841
  issue: 9
  year: 2018
  ident: 1391_CR23
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2017.74.7576
– volume: 31
  start-page: 507
  issue: 4
  year: 2020
  ident: 1391_CR134
  publication-title: Ann Oncol
  doi: 10.1016/j.annonc.2020.01.013
– volume: 4
  start-page: 1046
  issue: 9
  year: 2014
  ident: 1391_CR14
  publication-title: Cancer Discov
  doi: 10.1158/2159-8290.CD-14-0337
– volume: 14
  start-page: e126
  issue: 6
  year: 2019
  ident: 1391_CR90
  publication-title: J Thorac Oncol
  doi: 10.1016/j.jtho.2019.01.025
– volume: 13
  start-page: 7933
  year: 2020
  ident: 1391_CR154
  publication-title: Onco Targets Ther
  doi: 10.2147/OTT.S240775
– volume: 14
  start-page: 933
  issue: 5
  year: 2019
  ident: 1391_CR182
  publication-title: J Thorac Oncol
  doi: 10.1016/j.jtho.2019.02.001
– volume: 12
  start-page: 1728
  issue: 11
  year: 2017
  ident: 1391_CR109
  publication-title: J Thorac Oncol
  doi: 10.1016/j.jtho.2017.08.006
– volume: 126
  start-page: 149
  year: 2018
  ident: 1391_CR100
  publication-title: Lung Cancer
  doi: 10.1016/j.lungcan.2018.10.026
– volume: 7
  start-page: 387
  issue: 5
  year: 2019
  ident: 1391_CR192
  publication-title: Lancet Respir Med
  doi: 10.1016/S2213-2600(19)30084-0
– volume: 31
  start-page: 3327
  issue: 27
  year: 2013
  ident: 1391_CR40
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2012.44.2806
– volume: 12
  start-page: 1723
  issue: 11
  year: 2017
  ident: 1391_CR110
  publication-title: J Thorac Oncol
  doi: 10.1016/j.jtho.2017.06.017
– volume: 15
  start-page: 1351
  issue: 8
  year: 2020
  ident: 1391_CR188
  publication-title: J Thorac Oncol
  doi: 10.1016/j.jtho.2020.03.028
– volume: 20
  start-page: 924
  issue: 7
  year: 2019
  ident: 1391_CR191
  publication-title: Lancet Oncol
  doi: 10.1016/S1470-2045(19)30167-6
– volume: 22
  start-page: 2466
  issue: 11
  year: 2011
  ident: 1391_CR237
  publication-title: Ann Oncol
  doi: 10.1093/annonc/mdr003
– volume: 111
  start-page: 3813
  issue: 10
  year: 2020
  ident: 1391_CR29
  publication-title: Cancer Sci
  doi: 10.1111/cas.14593
– volume: 81
  start-page: 1262
  issue: 13_Supplement
  year: 2021
  ident: 1391_CR124
  publication-title: Cancer Res
  doi: 10.1158/1538-7445.AM2021-1262
– volume: 35
  start-page: 4027
  issue: 36
  year: 2017
  ident: 1391_CR170
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2017.73.9250
– volume: 10
  start-page: 248
  issue: 8
  year: 2018
  ident: 1391_CR2
  publication-title: Cancers (Basel)
  doi: 10.3390/cancers10080248
– year: 2022
  ident: 1391_CR47
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.21.02641
– volume: 10
  start-page: 4005
  issue: 11
  year: 2020
  ident: 1391_CR101
  publication-title: Am J Cancer Res
– volume: 13
  start-page: e219
  issue: 11
  year: 2018
  ident: 1391_CR174
  publication-title: J Thorac Oncol
  doi: 10.1016/j.jtho.2018.05.023
– volume: 81
  start-page: 1349
  issue: 11
  year: 2021
  ident: 1391_CR211
  publication-title: Drugs
  doi: 10.1007/s40265-021-01561-7
– volume: 21
  start-page: 1896
  issue: 8
  year: 2015
  ident: 1391_CR236
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-14-2082
– volume: 16
  start-page: 141
  issue: 2
  year: 2015
  ident: 1391_CR41
  publication-title: Lancet Oncol
  doi: 10.1016/S1470-2045(14)71173-8
– ident: 1391_CR219
  doi: 10.1158/2159-8290.CD-NB2022-0053
– volume: 15
  start-page: 1369
  issue: 12
  year: 2014
  ident: 1391_CR43
  publication-title: Lancet Oncol
  doi: 10.1016/S1470-2045(14)70452-8
– volume: 24
  start-page: 3097
  issue: 13
  year: 2018
  ident: 1391_CR66
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-17-2310
– volume: 14
  start-page: 369
  issue: 4
  year: 2019
  ident: 1391_CR70
  publication-title: Target Oncol
  doi: 10.1007/s11523-019-00652-6
– volume: 10
  start-page: 1736
  issue: 12
  year: 2015
  ident: 1391_CR83
  publication-title: J Thorac Oncol
  doi: 10.1097/JTO.0000000000000688
– volume: 75
  start-page: 2489
  issue: 12
  year: 2015
  ident: 1391_CR148
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-14-3167
– volume: 16
  start-page: 990
  issue: 8
  year: 2015
  ident: 1391_CR169
  publication-title: Lancet Oncol
  doi: 10.1016/S1470-2045(15)00121-7
– volume: 15
  start-page: 805
  issue: 8
  year: 2019
  ident: 1391_CR18
  publication-title: Future Oncol
  doi: 10.2217/fon-2018-0626
– volume: 73
  start-page: 755
  issue: 7
  year: 2013
  ident: 1391_CR213
  publication-title: Drugs
  doi: 10.1007/s40265-013-0050-2
– volume: 81
  start-page: 1107
  issue: 9
  year: 2021
  ident: 1391_CR51
  publication-title: Drugs
  doi: 10.1007/s40265-021-01533-x
– volume: 14
  start-page: 2847
  year: 2021
  ident: 1391_CR116
  publication-title: Onco Targets Ther
  doi: 10.2147/OTT.S298655
– volume: 362
  start-page: 2380
  issue: 25
  year: 2010
  ident: 1391_CR5
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa0909530
– volume: 108
  start-page: 228
  year: 2017
  ident: 1391_CR68
  publication-title: Lung Cancer
  doi: 10.1016/j.lungcan.2017.04.003
– volume: 71
  start-page: 7
  issue: 1
  year: 2021
  ident: 1391_CR1
  publication-title: CA Cancer J Clin
  doi: 10.3322/caac.21654
– volume: 29
  start-page: viii741
  year: 2018
  ident: 1391_CR58
  publication-title: Ann Oncol
  doi: 10.1093/annonc/mdy424.064
– volume: 146
  start-page: 358
  year: 2020
  ident: 1391_CR153
  publication-title: Lung Cancer
  doi: 10.1016/j.lungcan.2020.05.036
– volume: 367
  start-page: 1783
  issue: 19
  year: 2012
  ident: 1391_CR215
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa1209124
– volume: 12
  start-page: e85
  issue: 7
  year: 2017
  ident: 1391_CR132
  publication-title: J Thorac Oncol
  doi: 10.1016/j.jtho.2017.02.020
– volume: 112
  start-page: 3784
  issue: 9
  year: 2021
  ident: 1391_CR152
  publication-title: Cancer Sci
  doi: 10.1111/cas.15035
– volume: 15
  start-page: 1636
  issue: 10
  year: 2020
  ident: 1391_CR184
  publication-title: J Thorac Oncol
  doi: 10.1016/j.jtho.2020.07.014
– volume: 37
  start-page: 9051
  issue: 15_suppl
  year: 2019
  ident: 1391_CR224
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2019.37.15_suppl.9051
– volume: 76
  start-page: 283
  issue: 2
  year: 2016
  ident: 1391_CR206
  publication-title: Drugs
  doi: 10.1007/s40265-015-0537-0
– volume: 10
  start-page: 719
  issue: 12
  year: 2022
  ident: 1391_CR118
  publication-title: Ann Transl Med
  doi: 10.21037/atm-22-2436
– volume: 15
  start-page: 1369
  issue: 8
  year: 2020
  ident: 1391_CR114
  publication-title: J Thorac Oncol
  doi: 10.1016/j.jtho.2020.04.014
– year: 2022
  ident: 1391_CR172
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.21.02911
– volume: 10
  start-page: 259
  issue: 1
  year: 2019
  ident: 1391_CR82
  publication-title: Nat Commun
  doi: 10.1038/s41467-018-08074-0
– volume: 16
  start-page: 250
  issue: 2
  year: 2021
  ident: 1391_CR239
  publication-title: J Thorac Oncol
  doi: 10.1016/j.jtho.2020.10.008
– volume: 8
  start-page: 14768
  year: 2017
  ident: 1391_CR112
  publication-title: Nat Commun
  doi: 10.1038/ncomms14768
– volume: 385
  start-page: 51
  year: 2017
  ident: 1391_CR120
  publication-title: Cancer Lett
  doi: 10.1016/j.canlet.2016.11.008
– volume: 28
  start-page: 784
  issue: 4
  year: 2017
  ident: 1391_CR240
  publication-title: Ann Oncol
  doi: 10.1093/annonc/mdx017
– volume: 4
  start-page: 21
  year: 2020
  ident: 1391_CR145
  publication-title: NPJ Precis Oncol
  doi: 10.1038/s41698-020-0127-9
– volume: 134
  start-page: 7
  year: 2019
  ident: 1391_CR93
  publication-title: Lung Cancer
  doi: 10.1016/j.lungcan.2019.05.024
– volume: 18
  start-page: 148
  issue: 1
  year: 2018
  ident: 1391_CR12
  publication-title: BMC Cancer
  doi: 10.1186/s12885-018-4075-5
– volume: 12
  start-page: e181
  issue: 11
  year: 2017
  ident: 1391_CR91
  publication-title: J Thorac Oncol
  doi: 10.1016/j.jtho.2017.07.017
– volume: 10
  start-page: 8328
  issue: 23
  year: 2021
  ident: 1391_CR115
  publication-title: Cancer Med
  doi: 10.1002/cam4.4336
– volume: 35
  start-page: 2790
  issue: 24
  year: 2017
  ident: 1391_CR225
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2016.72.1894
– volume: 24
  start-page: 6195
  issue: 24
  year: 2018
  ident: 1391_CR56
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-18-1542
– volume: 30
  year: 2019
  ident: 1391_CR61
  publication-title: Ann Oncol
  doi: 10.1093/annonc/mdz260.048
– volume: 13
  start-page: 328
  issue: 6
  year: 2003
  ident: 1391_CR78
  publication-title: Trends Cell Biol
  doi: 10.1016/S0962-8924(03)00104-1
– volume: 27
  start-page: 575
  issue: 5
  year: 2019
  ident: 1391_CR141
  publication-title: Oncol Res
  doi: 10.3727/096504018X15344979253618
– volume: 4
  start-page: 210
  issue: 2
  year: 2018
  ident: 1391_CR177
  publication-title: JAMA Oncol
  doi: 10.1001/jamaoncol.2017.4427
– volume: 21
  start-page: e597
  issue: 6
  year: 2020
  ident: 1391_CR87
  publication-title: Clin Lung Cancer
  doi: 10.1016/j.cllc.2020.05.016
– volume: 25
  start-page: 64
  issue: 1
  year: 2019
  ident: 1391_CR217
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-18-1590
– volume: 28
  start-page: 2443
  issue: 10
  year: 2017
  ident: 1391_CR37
  publication-title: Ann Oncol
  doi: 10.1093/annonc/mdx359
– volume: 16
  start-page: 1859
  issue: 11
  year: 2021
  ident: 1391_CR158
  publication-title: J Thorac Oncol
  doi: 10.1016/j.jtho.2021.06.013
– volume: 38
  start-page: 115
  issue: 2
  year: 2020
  ident: 1391_CR171
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.19.01488
– volume: 22
  start-page: 4837
  issue: 19
  year: 2016
  ident: 1391_CR151
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-15-1915
– volume: 26
  start-page: 2654
  issue: 11
  year: 2020
  ident: 1391_CR94
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-19-3563
– volume: 17
  start-page: 577
  issue: 5
  year: 2016
  ident: 1391_CR7
  publication-title: Lancet Oncol
  doi: 10.1016/S1470-2045(16)30033-X
– volume: 27
  start-page: 992
  issue: 4
  year: 2021
  ident: 1391_CR202
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-20-1690
– volume: 534
  start-page: 129
  issue: 7605
  year: 2016
  ident: 1391_CR119
  publication-title: Nature
  doi: 10.1038/nature17960
– volume: 149
  start-page: 14
  year: 2021
  ident: 1391_CR173
  publication-title: Eur J Cancer
  doi: 10.1016/j.ejca.2021.02.019
– volume: 126
  start-page: 2704
  issue: 11
  year: 2020
  ident: 1391_CR65
  publication-title: Cancer
  doi: 10.1002/cncr.32809
– volume: 5
  start-page: 65
  issue: 1
  year: 2021
  ident: 1391_CR138
  publication-title: NPJ Precis Oncol
  doi: 10.1038/s41698-021-00208-w
– volume: 2
  start-page: vdaa125
  issue: 1
  year: 2020
  ident: 1391_CR238
  publication-title: Neurooncol Adv
– volume: 17
  start-page: 309
  issue: 2
  year: 2022
  ident: 1391_CR193
  publication-title: J Thorac Oncol
  doi: 10.1016/j.jtho.2021.09.014
– volume: 14
  start-page: e85
  issue: 5
  year: 2019
  ident: 1391_CR113
  publication-title: J Thorac Oncol
  doi: 10.1016/j.jtho.2019.01.015
– volume: 11
  start-page: 140
  issue: 1
  year: 2020
  ident: 1391_CR84
  publication-title: Thorac Cancer
  doi: 10.1111/1759-7714.13255
– volume: 65
  start-page: 9662
  issue: 14
  year: 2022
  ident: 1391_CR126
  publication-title: J Med Chem
  doi: 10.1021/acs.jmedchem.2c00704
– volume: 5
  start-page: 5
  issue: 1
  year: 2021
  ident: 1391_CR156
  publication-title: NPJ Precis Oncol
  doi: 10.1038/s41698-021-00149-4
– volume: 24
  start-page: 5610
  issue: 22
  year: 2018
  ident: 1391_CR203
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-18-0450
– volume: 111
  start-page: 84
  year: 2017
  ident: 1391_CR73
  publication-title: Lung Cancer
  doi: 10.1016/j.lungcan.2017.07.002
– volume: 8
  start-page: 49671
  issue: 30
  year: 2017
  ident: 1391_CR67
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.17913
– volume: 39
  start-page: 1279
  issue: 9
  year: 2021
  ident: 1391_CR197
  publication-title: Cancer Cell
  doi: 10.1016/j.ccell.2021.07.005
– volume: 117
  start-page: 38
  year: 2017
  ident: 1391_CR17
  publication-title: Crit Rev Oncol Hematol
  doi: 10.1016/j.critrevonc.2017.07.003
– volume: 379
  start-page: 2040
  issue: 21
  year: 2018
  ident: 1391_CR187
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa1810865
– volume: 19
  start-page: 702
  issue: 1
  year: 2019
  ident: 1391_CR106
  publication-title: BMC Cancer
  doi: 10.1186/s12885-019-5915-7
– volume: 29
  start-page: i28
  issue: suppl1
  year: 2018
  ident: 1391_CR52
  publication-title: Ann Oncol
  doi: 10.1093/annonc/mdx705
– volume: 21
  start-page: 3924
  issue: 17
  year: 2015
  ident: 1391_CR108
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-15-0560
– volume: 81
  start-page: 1467
  issue: 13_Supplement
  year: 2021
  ident: 1391_CR127
  publication-title: Cancer Res
  doi: 10.1158/1538-7445.AM2021-1467
– volume: 56
  start-page: 7025
  issue: 17
  year: 2013
  ident: 1391_CR16
  publication-title: J Med Chem
  doi: 10.1021/jm400822z
– volume: 26
  start-page: 2244
  issue: 9
  year: 2020
  ident: 1391_CR140
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-19-2321
– volume: 18
  start-page: 549
  issue: 4
  year: 2020
  ident: 1391_CR139
  publication-title: Mol Cancer Res
  doi: 10.1158/1541-7786.MCR-19-0956
– volume: 9
  start-page: 2596
  issue: 12
  year: 2020
  ident: 1391_CR164
  publication-title: Cells
  doi: 10.3390/cells9122596
– volume: 13
  start-page: e169
  issue: 9
  year: 2018
  ident: 1391_CR131
  publication-title: J Thorac Oncol
  doi: 10.1016/j.jtho.2018.04.007
– volume: 35
  start-page: 1288
  issue: 12
  year: 2017
  ident: 1391_CR20
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2016.70.3223
– volume: 121
  start-page: 725
  issue: 9
  year: 2019
  ident: 1391_CR53
  publication-title: Br J Cancer
  doi: 10.1038/s41416-019-0573-8
– volume: 9
  start-page: 829
  issue: 8
  year: 2021
  ident: 1391_CR243
  publication-title: Lancet Respir Med
  doi: 10.1016/S2213-2600(20)30455-0
– volume: 2
  start-page: 692
  issue: 4
  year: 2021
  ident: 1391_CR3
  publication-title: MedComm (2020)
– volume: 13
  start-page: 1415
  issue: 9
  year: 2018
  ident: 1391_CR69
  publication-title: J Thorac Oncol
  doi: 10.1016/j.jtho.2018.05.024
– volume: 36
  start-page: 2244
  issue: 22
  year: 2018
  ident: 1391_CR44
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2018.78.7994
– volume: 153
  start-page: 126
  year: 2021
  ident: 1391_CR79
  publication-title: Lung Cancer
  doi: 10.1016/j.lungcan.2020.12.039
– volume: 14
  start-page: 802
  issue: 5
  year: 2019
  ident: 1391_CR144
  publication-title: J Thorac Oncol
  doi: 10.1016/j.jtho.2018.12.038
– volume: 14
  start-page: e201
  issue: 9
  year: 2019
  ident: 1391_CR204
  publication-title: J Thorac Oncol
  doi: 10.1016/j.jtho.2019.04.013
– volume: 31
  start-page: 1397
  issue: 10
  year: 2020
  ident: 1391_CR234
  publication-title: Ann Oncol
  doi: 10.1016/j.annonc.2020.06.017
– volume: 378
  start-page: 113
  issue: 2
  year: 2018
  ident: 1391_CR22
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa1713137
– volume: 304
  start-page: 1497
  issue: 5676
  year: 2004
  ident: 1391_CR31
  publication-title: Science
  doi: 10.1126/science.1099314
– volume: 211
  start-page: 257
  year: 2018
  ident: 1391_CR15
  publication-title: Recent Results Cancer Res
  doi: 10.1007/978-3-319-91442-8_18
– volume: 128
  start-page: 33
  year: 2019
  ident: 1391_CR77
  publication-title: Lung Cancer
  doi: 10.1016/j.lungcan.2018.12.010
– volume: 35
  start-page: 3484
  issue: 30
  year: 2017
  ident: 1391_CR24
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2017.74.6065
– volume: 14
  start-page: 1152
  issue: 6
  year: 2020
  ident: 1391_CR160
  publication-title: Mol Oncol
  doi: 10.1002/1878-0261.12682
– volume: 63
  start-page: 4517
  issue: 9
  year: 2020
  ident: 1391_CR161
  publication-title: J Med Chem
  doi: 10.1021/acs.jmedchem.9b01392
– volume: 18
  start-page: 1454
  issue: 11
  year: 2017
  ident: 1391_CR8
  publication-title: Lancet Oncol
  doi: 10.1016/S1470-2045(17)30608-3
– volume: 29
  start-page: viii740
  year: 2018
  ident: 1391_CR57
  publication-title: Ann Oncol
  doi: 10.1093/annonc/mdy424.063
– volume: 17
  start-page: 558
  issue: 4
  year: 2022
  ident: 1391_CR245
  publication-title: J Thorac Oncol
  doi: 10.1016/j.jtho.2021.11.025
– volume: 35
  start-page: 3065
  issue: 26
  year: 2017
  ident: 1391_CR95
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2016.71.9096
– volume: 36
  start-page: 3298
  issue: 33
  year: 2018
  ident: 1391_CR222
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2018.78.7697
– volume: 14
  start-page: 1995
  issue: 11
  year: 2019
  ident: 1391_CR98
  publication-title: J Thorac Oncol
  doi: 10.1016/j.jtho.2019.07.016
– volume: 54
  year: 2021
  ident: 1391_CR241
  publication-title: Drug Resist Updat
  doi: 10.1016/j.drup.2020.100741
– volume: 18
  start-page: 112
  issue: 1
  year: 2019
  ident: 1391_CR146
  publication-title: Mol Cancer Ther
  doi: 10.1158/1535-7163.MCT-18-0591
– volume: 6
  start-page: 1048
  issue: 7
  year: 2020
  ident: 1391_CR198
  publication-title: JAMA Oncol
  doi: 10.1001/jamaoncol.2020.1260
– volume: 16
  start-page: 763
  issue: 7
  year: 2015
  ident: 1391_CR205
  publication-title: Lancet Oncol
  doi: 10.1016/S1470-2045(15)00021-2
– volume: 30
  start-page: vii16
  year: 2019
  ident: 1391_CR60
  publication-title: Ann Oncol
  doi: 10.1093/annonc/mdz413.058
– volume: 3
  start-page: 402
  issue: 4
  year: 2022
  ident: 1391_CR122
  publication-title: Nat Cancer
  doi: 10.1038/s43018-022-00351-8
– volume: 3
  start-page: e181
  issue: 4
  year: 2022
  ident: 1391_CR4
  publication-title: MedComm (2020)
– volume: 26
  start-page: 2073
  issue: 10
  year: 2015
  ident: 1391_CR26
  publication-title: Ann Oncol
  doi: 10.1093/annonc/mdv319
– volume: 11
  year: 2021
  ident: 1391_CR102
  publication-title: Front Oncol
  doi: 10.3389/fonc.2021.649843
– volume: 118
  start-page: 1
  year: 2018
  ident: 1391_CR72
  publication-title: Lung Cancer
  doi: 10.1016/j.lungcan.2018.01.015
– volume: 111
  start-page: 61
  year: 2017
  ident: 1391_CR86
  publication-title: Lung Cancer
  doi: 10.1016/j.lungcan.2017.07.006
– volume: 387
  start-page: 1540
  issue: 10027
  year: 2016
  ident: 1391_CR176
  publication-title: Lancet
  doi: 10.1016/S0140-6736(15)01281-7
– volume: 82
  start-page: 3328
  issue: 12_Supplement
  year: 2022
  ident: 1391_CR125
  publication-title: Cancer Res
  doi: 10.1158/1538-7445.AM2022-3328
– volume: 13
  start-page: 1138
  issue: 8
  year: 2018
  ident: 1391_CR179
  publication-title: J Thorac Oncol
  doi: 10.1016/j.jtho.2018.03.035
– volume: 4
  start-page: vdab188
  issue: 1
  year: 2022
  ident: 1391_CR229
  publication-title: Neurooncol Adv
– volume: 2
  start-page: 377
  issue: 4
  year: 2021
  ident: 1391_CR55
  publication-title: Nat Cancer
  doi: 10.1038/s43018-021-00195-8
– volume: 15
  start-page: 1758
  issue: 11
  year: 2020
  ident: 1391_CR233
  publication-title: J Thorac Oncol
  doi: 10.1016/j.jtho.2020.06.018
– volume: 20
  start-page: 17
  issue: 1
  year: 2021
  ident: 1391_CR76
  publication-title: Mol Cancer
  doi: 10.1186/s12943-021-01307-9
– volume: 14
  start-page: 335
  issue: 3
  year: 2019
  ident: 1391_CR166
  publication-title: Target Oncol
  doi: 10.1007/s11523-019-00644-6
SSID ssj0061920
Score 2.6434388
SecondaryResourceType review_article
Snippet Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are the preferential options for advanced non-small cell lung cancer (NSCLC) patients...
Abstract Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are the preferential options for advanced non-small cell lung cancer (NSCLC)...
SourceID doaj
pubmedcentral
proquest
gale
pubmed
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
StartPage 173
SubjectTerms Binding sites
Cancer
Cancer therapies
Carcinoma, Non-Small-Cell Lung - drug therapy
Carcinoma, Non-Small-Cell Lung - genetics
Care and treatment
Chemotherapy
Clinical trials
Drug Resistance, Neoplasm
EGFR-TKIs
Epidermal growth factor
Epidermal growth factor receptors
ErbB Receptors - genetics
Etiology
Genetic aspects
Health aspects
Hematology
Humans
Kinases
Ligands
Lung cancer
Lung cancer, Non-small cell
Lung cancer, Small cell
Lung Neoplasms - drug therapy
Lung Neoplasms - genetics
Metastases
Mutation
Non-small cell lung carcinoma
NSCLC
Oncology
Osimertinib
Protein-tyrosine kinase receptors
Resistance mechanisms
Review
Small cell lung carcinoma
Targeted cancer therapy
Targeted therapy
Therapeutic strategy
Tyrosine
SummonAdditionalLinks – databaseName: Health & Medical Collection
  dbid: 7X7
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1La9wwEBZtCqWX0nfcpqkKhR6KyNp6-lTSkk0opIeyhb0JWZaThX0k693_3xlZdmIKua7GXlmj0cwnzXwi5EvdQNgtcsOk5wBQGsCsZeNL5iforLjOc4XFyZe_1cVf8Wsu52nDrU1plf2aGBfqeuNxj_yk0BLBA3i_7ze3DG-NwtPVdIXGY_IEqcswpUvPB8CF2GDSF8oYddLmeCzIMH8dAx_o2sgZRc7-_1fme65pnDZ5zw9NX5DnKYCkp53GX5JHYf2KPL1MR-SvydXsrqKKtrueCYJCcErPzqd_2GqP8WVNAfezduWWS4qb93QJVk89zoEtTWSrLcVdWrppFyvMvl4vKgrgHANOkHpDZtOz2c8Llm5TYF6WYsd4cJUsvFDONAo0FLnEjKuMA0RY6xIQqQsylE3uDK8grPNG15NKysY1XHn-lhxAx8IhoaUuTOB53lTcAd6pjVMFKBicf224Kl1G8n5UrU9M43jhxdJGxGGU7TRhQRM2asKKjHwbnrnpeDYelP6ByhokkSM7_rDZXtlkclY5rQEjF9BLLpR3FVcTHrx0SKpvKp6RT6hq2xWcDpZuTwFvCFzK4G--Rgm0dfgA71LJAgwDsmaNJI9GkmCjftzcTyeb1ojW3s3ojHwemvFJzHtbh80-ynAIMqDHGXnXzb7ho7kSphD4cj2al6NRGbesF9eRQbzU8NbcvH-4Wx_IswKNBZN3zBE52G334SOEYLvqONrZP5AfLcQ
  priority: 102
  providerName: ProQuest
– databaseName: Scholars Portal Journals: Open Access
  dbid: M48
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1bi9QwFA7rCuKLeLe6agTBB6lOLk3SB5FVdlyE8UFmYd9CkrbrQKej0xnQf-856cUtLj752py06bkk35fLCSEviwpgt2QmzYIAglIBZ82rkKdhhoOV0IwpPJy8-KJOz-Tn8-z8gAzXHfUKbK-kdnif1Nm2fvPzx6_3EPDvYsAb9bZluNyX4r50BDTwyWvkOoxMGgN1IcdVBeQKs-HgzJX1JoNTzOH_d099aaiabqO8NC7Nb5NbPaCkx50H3CEHZXOX3Fj0S-b3yMXyzwkr2u6GzBAUwCo9-TT_mq73iDcL2myatF27uqY4mU9r6AVoQJ_Y0j75aktx1pZu2tUad2M3K0-BrCMABan7ZDk_WX48TfvbFdKQ5XKXitL5jAepnKkUWCzmFjPOGwcMsdA5MFRXZmVeMWeEB5gXjC5mPssqVwkVxANyCA0rHxGaa25KwVjlhQP-UxinOBgcwEBhhMpdQtigVRv6zON4AUZtIwMxynaWsGAJGy1hZUJej3W-d3k3_in9AY01SmLO7Phgs72wfQha5bQGzsyhlUKq4LxQM1GGzGGSfeNFQp6jqW13AHWMfHsM_ENi1wafeRUl0BvhB4LrjzCAGjCL1kTyaCIJMRumxYM72cHlLdcZ0mPAdwl5MRZjTdwH15SbfZQRADqgxQl52Hnf-NNCScMlvlxP_HKilWlJs_oWM4rnGt7KzOP_ocYn5CbHkGI85fyIHO62-_IpALedfxaj8TcW8j2U
  priority: 102
  providerName: Scholars Portal
Title Therapeutic strategies for EGFR-mutated non-small cell lung cancer patients with osimertinib resistance
URI https://www.ncbi.nlm.nih.gov/pubmed/36482474
https://www.proquest.com/docview/2755601554
https://www.proquest.com/docview/2753303479
https://pubmed.ncbi.nlm.nih.gov/PMC9733018
https://doaj.org/article/6a779782b3a346cab3603ec5a47948b3
Volume 15
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3di9NAEF_0BPFF_DbeWVcQfJBw3exnHnvSehR6yFmhb8tms9FC25NL-__fzObDBkFffEkhO0k3OzM780tmf0vIh7KCtFswk0rPAaBUgFnzyuepH2Ow4poxhYuTF1fq8ruYr-TqaKsvrAlr6IGbgTtXTmtAOlnBHRfKu4KrMQ9eOqRGN0Xk-YSY14GpZg5GVDDulsgYdV4z_CCYYuU6pjzQqUEYimz9f87JR0FpWDB5FIFmT8jjNnWkk6bLT8m9sHtGHi7aj-PPyY_l77VUtN53HBAU0lI6_TK7TrcHzCxLCog_rbdus6H42p5uwN-pR-3f0pZmtab4fpbe1Ost1l3v1gUFWI6pJki9IMvZdPn5Mm33UUi9zMU-5cEVMvNCOVMp0E1kETOuMA6wYKlzwKIuyJBXzBleQELnjS7HhZSVq7jy_CU5gY6F14TmOjOBM1aBNgDplMapDFQLYb80XOUuIawbVetbjnHc6mJjI9YwyjaasKAJGzVhRUI-9df8ahg2_ip9gcrqJZEdO54Am7Gtzdh_2UxC3qGqbbPUtPdxOwGkIXASg7_5GCXQy-EBvGsXK8AwIF_WQPJsIAne6YfNnTnZdnaobaYlAmHI5BLyvm_GK7HibRduDlGGQ3oBPU7Iq8b6-ofmSphM4M31wC4HozJs2a1_Ru7wXMNdmXnzP4bxlDzK0KWwuMeckZP97SG8hRRtX4zIfb3SI_JgMpl_m8PvxfTq6_Uo-igcF8LcAcqEOo4
linkProvider Directory of Open Access Journals
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3db9MwED-NTgJeJj5Hx2BGAvGAojVx4jgPCG3Q0rG1QlOR9mY5jjMqtcloWiH-KP5H7vK1RUh722t8dhzf-e5-8d0Z4G2Sotvtu9IJDEeAkiJmjVITOWZAxoqHrisoOXkyFeMf_reL4GIL_ja5MBRW2ejEUlEnuaF_5IdeGBB4QOv36eqXQ7dG0elqc4VGJRan9s9vhGzFx5MvyN93njcazj6PnfpWAccEkb92uNVx4BlfaJkKnGlZU0vqWGpERkkYITLTNrBR6mrJY3RvjAyTQRwEqU65MByHvQfbPsduPdg-Hk6_nzeqn8DIoMnMkeKwcOkc0qGAefK0cC061q-8JOB_U3DDFnbjNG8YvtEj2Kk9VnZUidhj2LLZE7g_qc_kn8Ll7DqFixXrpvQEQ2-YDb-Ozp3lhhzahGV55hRLvVgwOi1gC1QzzJDQrVhd3bVg9FuY5cV8SeHe2TxmK1uQh4tUz2B2Fwv9HHo4MfsCWBR60nLXTWOuEWAlUgsPJQq9jURyEek-uM2qKlOXNqcbNhaqhDhSqIoTCjmhSk4ovw8f2j5XVWGPW6mPiVktJRXlLh_kq0tV73EldBgiKPdwltwXRscoI9yaQFMVfxnzPhwQq1WV4dqqFnWEAMcn3YmveV9SkHLBDzC6zpHAZaAyXR3K_Q4lKgXTbW7ESdVKqVDXW6gPb9pm6kmBdpnNNyUNR68GZ9yH3Ur62o_mwpeeT4OHHbnsrEq3JZv_LEuWRyGO6sq926d1AA_Gs8mZOjuZnr6Ehx5tHIockvvQW6829hX6f-v4db3rGKg73uf_ADWPa3M
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Therapeutic+strategies+for+EGFR-mutated+non-small+cell+lung+cancer+patients+with+osimertinib+resistance&rft.jtitle=Journal+of+hematology+and+oncology&rft.au=Kai+Fu&rft.au=Fachao+Xie&rft.au=Fang+Wang&rft.au=Liwu+Fu&rft.date=2022-12-08&rft.pub=BMC&rft.eissn=1756-8722&rft.volume=15&rft.issue=1&rft.spage=1&rft.epage=32&rft_id=info:doi/10.1186%2Fs13045-022-01391-4&rft.externalDBID=DOA&rft.externalDocID=oai_doaj_org_article_6a779782b3a346cab3603ec5a47948b3
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1756-8722&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1756-8722&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1756-8722&client=summon